Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

INTUITIVE SURGICAL INC Director's Dealing 2024

Jul 31, 2024

29809_dirs_2024-07-31_cc4d1333-89ce-426d-9799-c8a2fa36556e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INTUITIVE SURGICAL INC (ISRG)
CIK: 0001035267
Period of Report: 2024-07-30

Reporting Person: GUTHART GARY S (Director, CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-07-30 Common Stock M 25200 $57.1111 Acquired 40558 Direct
2024-07-30 Common Stock S 23388 $443.0698 Disposed 17170 Direct
2024-07-30 Common Stock G 12500 $0.0 Disposed 1191144 Indirect
2024-07-30 Common Stock S 3720 $445.0662 Disposed 23640 Indirect
2024-07-30 Common Stock S 3720 $445.1165 Disposed 23640 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-07-30 Non-Qualified Stock Option (right to buy) $57.1111 M 25200 Disposed 2025-02-17 Common Stock (25200) Direct

Footnotes

F1: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 30, 2025.

F2: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $437.94 to $447.76 as follows: 1,797 shares sold at $437.94 to $438.93; 1,345 shares sold at $439.00 to $440.00; 3,108 shares sold at $440.11 to $441.10; 5,000 shares sold at $442.35 to $443.29; 5,182 shares sold at $443.38 to $444.36; 4,556 shares sold at $444.39 to $445.25; 800 shares sold at $445.62 to $445.80; and 1,600 shares sold at $447.00 to $447.76. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: The shares were donated to a Donor Advised Fund (DAF) in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 30, 2025.

F4: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $443.66 to $447.85 as follows: 1,465 shares sold at $443.66 to $444.31; 1,601 shares sold at $444.93 to $445.80; 554 shares sold at $446.46 to $447.08; and 100 shares sold at $447.85. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $443.66 to $447.85 as follows: 1,552 shares sold at $443.66 to $444.62; 1,400 shares sold at $444.84.00 to $445.29; 568 shares sold at $446.46 to $447.33; and 200 shares sold at $447.76 to $447.85. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F6: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.